Whitney Silkworth

Inhibition of <i>KRAS</i> -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

Zehua Zhu, Amir Reza Aref, Travis J. Cohoon et al. · Cancer Discovery · 2014 · 193 citations · Full text

Medicine, Cancer Biology, Oncology +15

A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells

Michel Weïwer, James Spoonamore, Jingqiang Wei et al. · ACS Medicinal Chemistry Letters · 2012 · 147 citations · Full text

Medicine, Oncology, Pharmacology +15

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

Jennifer A. Lo, Masayoshi Kawakubo, Vikram R. Juneja et al. · Science Translational Medicine · 2021 · 97 citations · Full text

Life Sciences, Immunology, Oncology +17

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

Tuoping Luo, Kristina Masson, Jacob D. Jaffe et al. · Proceedings of the National Academy of Sciences · 2012 · 94 citations · Full text

Medicine, Molecular Biology, Oncology +13

Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis

Shinichiro Kato, Qing Yu Weng, Megan L. Insco et al. · Cancer Discovery · 2020 · 73 citations · Full text

Medicine, Genetics, Oncology +17